Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Hit Repeat

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Apr 18, 2024 7:31am

83 Views

Post# 35995366

RE:RE:RE:RE:RE:RE:RE:RE:Hit Repeat

I am having a look. Mixed reviews with analysts but they may well do well in the coming months and years, I don't know. I don't have an issue with other biotechs and their products, particularly if they're going to do some good. Never see the need for dopes like yourself coming on here to bash a drug that's proving out in trials, as if it's a threat to their own stock holdings. Unless of course you have a vested interest in the stock not performing well! Could that be it?

I'll say this again, go look at Agenus. Great test case for why institutional and inside ownership isn't a requirement for success, or failure.

<< Previous

Bullboard Posts

Next >>

The deep connection between mining and First Nations in Canada